Medicare Analysis Confirms Some ‘Preferred Pharmacy' Drug Plans are Costlier to Plan Sponsors than Traditional Benefit Designs



Alexandria, Va. July 3, 2013 - A new analysis by the U.S. Centers for Medicare & Medicaid Services (CMS) validates the questions about “preferred pharmacy” drug plans1 that have been raised by Medicare officials, 19 U.S. Senators, 31 U.S. Representatives, MedPAC and the National Community Pharmacists Association (NCPA).

In analyzing 2012 prescription drug claims in the Medicare Part D drug benefit, CMS finds that “prices are sometimes higher in certain preferred networks,” compared to traditional plans offering patients greater choice, and that, because enrollment in such plans has increased, “the impact of higher preferred network prices on the program as a whole is likely to become increasingly significant.”

In response, NCPA CEO B. Douglas Hoey, RPh, MBA, issued the following statement:

“Medicare authorized the introduction of preferred pharmacy plans into the Part D drug benefit on the assumption that they would lower Medicare’s costs. Instead, CMS’ analysis has concluded that some of these preferred pharmacy plans are increasing its costs, to the disadvantage of beneficiaries and taxpayers and in apparent violation of Medicare regulations. In most of these instances the health plans themselves essentially verified Medicare’s findings.

“NCPA has opposed these preferred pharmacy plans because they are not in the best interest of many patients, they have been deceptively marketed and they amount to government-sanctioned bias against small business, community pharmacies since they do not require plans to offer participation to all pharmacies. Seniors in rural areas in particular may have to travel 20 miles or more to obtain their prescription drugs from a preferred pharmacy. A community pharmacist in the Northern Mariana Islands reports that his Medicare patients’ closest preferred pharmacy is nine hours away by plane in Hawaii! His request to participate in the plan at the same reimbursement rates of other preferred pharmacies was reportedly denied.

“Earlier this year NCPA analyzed 2013 data on the Medicare Plan Finder website to compare the full costs of four commonly used medications between preferred and non-preferred pharmacies. That analysis found that most of the time the full cost was more expensive at preferred pharmacies than at non-preferred pharmacies.

“There is a simple solution to this problem, which Medicare itself has endorsed as ‘the best way to encourage price competition and lower costs.’ Allow any legitimate pharmacy provider that is willing to accept a health plan’s terms and conditions, including reimbursement, to participate in that plan’s network, whether it is a preferred network or a traditional one. That gives patients greater freedom to choose a pharmacy that best meets their personal health and medication adherence needs without increasing costs to the health plan or its sponsor, in this case Medicare.

“Moreover, this is a cautionary tale for public and private health plan sponsors alike to keep in mind when pharmacy benefit managers or others attempt to foist so-called preferred network pharmacy plans on patients to deny their choice of pharmacy.”

1Preferred pharmacy plans differ from traditional drug benefit plans in that they impose limits on patient choice by establishing tiers of pharmacies. Most pharmacies are allowed to participate as “network” pharmacies in order to allow the plan to satisfy Medicare’s geographic access requirements, but only a limited number of pharmacies are allowed by the plan to participate as a “preferred” pharmacy. Most preferred network plans do not offer or allow independently owned pharmacies and regional chains to participate as a preferred pharmacy in their network.

Related Videos
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg -
Image credit: |
Medical team -- Image credit: Flamingo Images |
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin -
© 2024 MJH Life Sciences

All rights reserved.